The articles presented here provide the NACB's updated recommendations for the rapidly evolving topics of Clinical Utilization of
Biochemical Markers in Acute Coronary Syndromes and Analytical Issues for
Biochemical Markers of Acute Coronary Syndromes.
Cerebral ischemia also initiates an inflammatory response in the brain and triggers the release of
biochemical markers into the blood.
The purpose of this research is to investigate how cardiovascular risk genes,
biochemical markers, and currently available cardiovascular functional studies improve the way cardiovascular disease is diagnosed, predicted and managed.
Our expert radiologists and scientists are innovators in all aspects of medical imaging and
biochemical markers in drug development, and have pioneered many methods used in today's clinical trials.
The chapter "Assessing the Risk of Bone Disease and Fracture" discusses many aspects of bone mass measurement, but relegates
biochemical markers of bone turnover to the subsection "Looking to the Future: Potential Complements to BMD" (1).
The research provides early data on the usefulness of Singulex' Erenna assays to facilitate more specific detection of cardiac troponin I, a powerful
biochemical marker for myocardial necrosis.
The
biochemical marker will tell you whether or not patients will lose bone if they are not treated and whether they will gain bone if they are treated.
The purpose of the monograph is to give an overview of past, present, and possible future
biochemical markers for myocardial injury and to address each marker's analytical, technical, and clinical performance, as well as outcome assessments, including risk stratification.
The serum TfR-ferritin index is the best
biochemical marker of functional iron deficiency, with a cutoff value of 1.
FibroTest is a
biochemical marker of liver fibrosis and ActiTest is a
biochemical marker of inflammation and necrosis of the liver.
These included a global licensing agreement to develop assay kits for the ADAM12
biochemical marker, which has broad potential in maternal health screening for fetal chromosomal abnormalities; and the securing of global rights for PP13 (Placental Protein 13), a new prospective biomarker for identifying patients at risk for pre-eclampsia in the first trimester.
Ischemia Technologies is developing diagnostic tests for ischemia based on detection of the
biochemical marker Ischemia Modified Albumin (IMA(TM)).
